[1]陈　偲,王　颖a,谢生茂,等.GPRC5A对肝癌细胞增殖、凋亡和氧化应激的影响及作用机制探讨[J].现代检验医学杂志,2021,36(06):10-16.[doi:10.3969/j.issn.1671-7414.2021.06.003]
　CHEN Si,WANG Ying,WU Jian-jun,et al.Effects of GPRC5A on Proliferation, Apoptosis and Oxidative Stress of Hepatocellular Carcinoma Cells and Its Mechanism[J].Journal of Modern Laboratory Medicine,2021,36(06):10-16.[doi:10.3969/j.issn.1671-7414.2021.06.003]
点击复制

GPRC5A对肝癌细胞增殖、凋亡和氧化应激的影响及作用机制探讨()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第36卷
期数:
2021年06期
页码:
10-16
栏目:
论　著
出版日期:
2021-12-15

文章信息/Info

Title:
Effects of GPRC5A on Proliferation, Apoptosis and Oxidative Stress of Hepatocellular Carcinoma Cells and Its Mechanism
文章编号:
1671-7414（2021）06-010-08
作者:
陈　偲1; 王　颖2a; 谢生茂1; 李忠辉2b; 武建军3
（1.解放军联勤保障部队第九六九医院消化内分泌科,呼和浩特 010010; 2.内蒙古包钢医院a.老年病科;b.肿瘤内科，内蒙古包头 014010; 3. 内蒙古自治区人民医院消化内科，呼和浩特 010010 ）
Author(s):
CHEN Si;  WANG Ying;  WU Jian-jun;  et al
（1. Department of Gastroenterology and Endocrinology, the 969 Hospital of the Toint Logistics Support Force of the People’s Liberation Army, Hohhot 010010,China;2a. Department of Geriatrics ;2b .Department of Oncology, Baogang Hospital of Inner Mongolia City, Inner Mongolia Baotou 014010,China;3.Department of Digestive Medicine, People’s Hospital of Inner Mongolia Autonomous Region , Hohhot 010010,China）
关键词:
G蛋白偶联受体家族C群5成员A（GPRC5A）; 肝癌; 增殖; 氧化应激; 凋亡; STAT3/Socs3/c-MYC
分类号:
R735.7；R730.43
DOI:
10.3969/j.issn.1671-7414.2021.06.003
文献标志码:
A
摘要:
目的　通过检测G蛋白偶联受体家族C群5成员A（G protein coupled receptor C type group 5 member A, GPRC5A）在肝癌组织及细胞中的表达，探讨GPRC5A对肝癌细胞增殖、凋亡、氧化应激的影响及其相关作用机制。方法　收集2018年12月～2019年11月在解放军联勤保障部队第九六九医院行手术治疗的38例肝癌患者癌组织及配对癌旁正常组织样本；另选取人正常肝上皮细胞株HL-7702和人肝癌细胞株（HepG2，HCCLM3，HuH-7和MHCC-97H）进行研究。采用实时荧光定量聚合酶链反应（qRT-PCR）检测肝癌组织、癌旁正常组织及肝癌细胞、正常肝上皮细胞中GPRC5A表达量。通过转染pcDNA3.1-GPRC5A质粒构建过表达GPRC5A肝癌细胞株，采用MTT实验和V-FITC/PI凋亡试剂盒分别检测过表达GPRC5A对肝癌细胞增殖、凋亡的影响。采用活性氧指示剂DCFH-DA检测细胞中氧化应激相关因子活性氧（ROS），NAD+/NADH和三磷酸腺苷（ATP）水平。采用Western blot实验检测凋亡相关蛋白caspase-3及上皮生长因子（VEGF）蛋白表达水平。结果　肝癌组织中GPRC5A表达较癌旁正常组织显著降低（0.34±0.09 vs 0.73±0.10），差异有统计学意义（t=17.869，P<0.01）。肝癌细胞HepG2（0.35±0.06），HCCLM3（0.38±0.10），HuH-7（0.53±0.07），MHCC-97H（0.67±0.06）中GPRC5A表达量显著低于人正常肝上皮细胞HL-7702中的GPRC5A表达量（1.00±0.08），差异有统计学意义（t=5.716~11.258, 均P<0.05）。pcDNA3.1-GPRC5A组转染36 h细胞增殖吸光度（A）值（0.94±0.16）显著低于对照组（1.49±0.05）和pcDNA3.1组（1.45±0.07）（F=25.640，P<0.01）。GPRC5A过表达组VEGF（0.98±0.04）表达量较对照组（2.94±0.15）和pcDNA3.1组（2.89±0.11）显著降低（F=310.450，P<0.001）。pcDNA3.1-GPRC5A组细胞中ROS（182.12±13.42）水平显著高于对照组（101.23±11.20）和pcDNA3.1组（98.30±10.26）（F=49.577，P<0.001）；NAD+/NADH（35.24±6.43）及ATP（55.34±6.51）水平显著低于对照组（100.25±12.41，100.17±14.36）和pcDNA3.1组（97.86±9.67，102.23±11.02）（F=42.338，17.077，P<0.05）。GPRC5A过表达组细胞凋亡率高于对照组和pcDNA3.1组；细胞凋亡蛋白caspase-3（2.61±0.16）表达量也高于对照组（1.00±0.11）和pcDNA3.1组（1.01±0.02）（F=202.843，P<0.001）。pcDNA3.1-GPRC5A组细胞中p-STAT3表达量（0.43±0.06）显著低于对照组（1.00±0.13）和pcDNA3.1组（1.03±0.12）（F=29.476，P<0.001）；pcDNA3.1-GPRC5A组下游基因Socs3（0.47±0.05），c-MYC（0.54±0.06）表达量也显著低于对照组（1.01±0.05，1.00±0.04）和pcDNA3.1组（0.98±0.09，1.02±0.06）（F=63.275，75.409，P<0.001）。肝癌组织中STAT3与GPRC5A表达量呈显著负相关（r=-0.746，P<0.01）。过转染pcDNA3.1-STAT3或pcDNA3.1-NLRP3后显著逆转了pcDNA3.1-GPRC5A对肝癌细胞的抑制作用（P<0.05）。结论　GPRC5A低表达可能通过调节STAT3/Socs3/c-MYC信号和炎症反应抑制了肝癌细胞的增殖，诱导肝癌细胞的氧化应激和凋亡。
Abstract:
Objective　To explore the effects of GPRC5A on the proliferation, apoptosis and oxidative stress of liver cancer cells and its related mechanism by detecting the expression of GPRC5A in liver cancer tissues and cells. Methods　A total of 38 patients with liver cancer who underwent surgical treatment in the 969th Hospital of the Joint Logistics Support Force of the People’s Liberation Army from December 2018 to November 2019 were collected for their cancer tissue samples and matched adjacent normal tissue samples. Human normal liver epithelial cell lines HL-7702 and human hepatocellular carcinoma cell lines (HepG2, HCCLM3, Huh-7 and MHCC-97H) were selected for the study. QRT-PCR was used to detect the expression of GPRC5A in liver cancer tissues, adjacent normal tissues, liver cancer cells and normal liver epithelial cells. The overexpressed GPRC5A hepatoma cell line was constructed by transfection of pcDNA3.1-GPRC5A plasmid. The effects of overexpression of GPRC5A on the proliferation and apoptosis of hepatoma cells were detected by MTT assay and V-FITC/PI apoptosis kit, respectively. The levels of reactive oxygen species (ROS), NAD+/NADH and adenosine triphosphate (ATP) were detected by DCFH-DA, a reactive oxygen indicator. Western blot assay was used to detect the expression levels of apoptosis-related protein caspase-3 and epithelial growth factor (VEGF). Results　The expression of GPRC5A in HCC tissues was significantly lower than that in adjacent normal tissues (0.34±0.09 vs 0.73±0.10), the difference was statistically significant(t=17.869, P<0.01). The expression level of GPRC5A in HepG2 cells (0.35±0.06), HCClM3 cells (0.38±0.10), Huh-7 cells (0.53±0.07), and MHCC-97H (0.67±0.06) was significantly lower than that in HL-7702 (1.00±0.08), the differences were statistically significant(t=5.716~11.258, P<0.05). The A value of pcDNA3.1-GPRC5A group (0.94±0.16) at 36 h after transfection was significantly lower than that of Control group (1.49±0.05) and pcDNA3.1 group (1.45±0.07) (F=25.640, P<0.01). The expression of VEGF in GPRC5A overexpression group was significantly decreased (0.98±0.04) compared with that in control group (2.94±0.15) and PCDNA3.1 group (2.89±0.11) (F=310.450, P<0.001). The level of ROS (182.12±13.42) in PCDNA3.1-GPRC5A group was significantly higher than that in control group (101.23±11.20) and PCDNA3.1 group (98.30±10.26) (F=49.577, P<0.001). NAD+/NADH (35.24±6.43) and ATP (55.34±6.51) levels were significantly lower than those in control group (100.25±12.41, 100.17±14.36) and PCDNA3.1 group (97.86±9.67, 102.23±11.02) (F=42.338, 17.077, P<0.05). The apoptosis rate of GPRC5A overexpression group was higher than that of control group and pcDNA3.1 group. The expression level of apoptosis protein caspase-3 (2.61±0.16) was also higher than that of control group (1.00±0.11) and PCDNA3.1 group (1.01±0.02) (F=202.843, P<0.001). The expression level of p-STAT3 in PCDNA3.1-GPRC5A group (0.43±0.06) was significantly lower than that in control group (1.00±0.13) and PCDNA3.1 group (1.03±0.12) (F=29.476, P<0.001). The expression levels of downstream gene SOCS3 and c-myc in pcDNA3.1-GPRC5A group were also significantly lower than those in control group(1.01±0.05, 1.00±0.04) and pcDNA3.1 group (0.98±0.09, 1.02±0.06) (F=63.275 and 75.409, all P<0.001). There was a significant negative correlation between STAT3 and GPRC5A expression in liver cancer (r=-0.746, P<0.01). The overtransfection of pcDNA3.1-STAT3 or pcDNA3.1-NLRP3 significantly reversed the inhibitory effect of pcDNA3.1-GPRC5A on HCC cells (P<0.05). Conclusion　GPRC5A may inhibit the proliferation of HCC cells by regulating STAT3/ SOCS3 / c-MYC signaling and inflammatory response, and induce oxidative stress and apoptosis of HCC cells. The low expression of GPRC5A may inhibit the proliferation of HCC cells by regulating STAT3/ SOCS3 / c-MYC signaling and inflammatory response, and induce oxidative stress and apoptosis of HCC cells.

参考文献/References:

[1] 张振，潘晴，刘旭，等．circRNA 与肿瘤发生的研究进展[J]．现代检验医学杂志,2018,33(2):157-159，164.ZHANG Zhen, PAN Qing, LIU Xu, et al. Researchprogress of the relationship between circular RNAand tumorigenesis [J]. Journal of Modern LaboratoryMedicine,2018,33(2):157-159, 164.
[2] GUO Wenzheng , HU Min , WU Jingjing , et al.GPRC5A depletion enhances the risk of smokinginducedlung tumorigenesis and mortality[J].B iome d i c i n e & P h ar m ac o t h e r a p y, 2 0 1 9 ,114:108791.
[3] JIN Er, LI Chao, LI Yiwei， et al. GPRC5A suppressesthe proliferation of non-small cell lung cancer underwild type p53 background[J]. Experimental LungResearch, 2020, 46(7): 226-233.
[4] KLASCHIK K, HAUKE J, NEIDHARDT G, et al. TheGPRC5A frameshift variant c.183del is not associatedwith increased breast cancer risk in BRCA1 mutationcarriers[J]. International Journal of Cancer, 2019,144(7): 1761-1763.
[5] TSAI M H, PAI L M, LEE C K. Fine-Tuning oftype I interferon response by STAT3[J]. Frontiers inImmunology, 2019, 10: 1448.
[6] 元建华，张曙波，李建旺，等．GPRC5A、SOCS3和STAT3 在结直肠癌组织中的表达及相关性分析[J]. 中国癌症防治杂志,2019,11(6):518-522.YUAN Jianhua，ZHANG Shubo，LI Jianwang,et al. Expression and correlation of GPRC5A,SOCS3 and STAT3 in colorectal cancer tissues[J]. Chinese Journal of Oncology Prevention andTreatment,2019,11(6):518-522.
[7] 张鑫浩，张涛元，李俏，等．基于GEO 芯片数据的肝癌关键生物标志物的筛选与鉴定及生物信息学分析[J]．现代检验医学杂志,2020,35(4):26-31.ZHANG Xinhao, ZHANG Taoyuan，LI Qiao, et al.Screening,identification and bioinformatics analysisof Key biomarkers for hepatocellular carcinoma basedon GEO chip data [J]. Journal of Modern LaboratoryMedicine,2020,35(4):26-31.
[8] WANG Chong, YANG Lei, LIANG Zikun, et al. Longtermsurvival and prognostic factors of pulmonarymetastasectomy in liver cancer: a systematic reviewand meta-analysis[J]. World Journal of Surgery, 2018,42(7): 2153-2163.
[9] 吴良银, 李文丽, 刘俊. 肝细胞癌患者生存预后相关长链非编码RNA(LncRNA) 的生物信息学分析[J].现代检验医学杂志,2019,34(4):18-21.WU Liangyin, LI Wenli, LIU Jun. Bioinformaticsanalysis of long-chain non-coding RNA related tosurvival and prognosis in patients with hepatocellularcarcinoma[J]. Journal of Modern LaboratoryMedicine,2019,34(4):18-21.
[10] QIAN Xuetian, JIANG Chengfei, SHEN Shanshan, etal. GPRC5A: an emerging prognostic biomarker forpredicting malignancy of pancreatic cancer based onbioinformatics analysis[J]. Journal of Cancer, 2021,12(7): 2010-2022.
[11] SONG Hongyong, SUN Beibei, LIAO Yueling,et al. GPRC5A deficiency leads to dysregulatedMDM2 via activated EGFR signaling for lung tumordevelopment[J]. International Journal of Cancer, 2019,144(4): 777-787.
[12] SAWADA Y, KIKUGAWA T, IIO H, et al. GPRC5Afacilitates cell proliferation through cell cycleregulation and correlates with bone metastasis inprostate cancer[J]. International Journal of Cancer,2020, 146(5): 1369-1382.
[13] 谭元元．卡衣赛尔·卡哈尔, 程秀琴.GPRC5A 对喉癌细胞增殖、氧化应激和细胞凋亡的影响[J]. 中国医师杂志, 2021, 23(3):359-365.TAN Yuanyuan, KAYISAIER·Kahaer, CHENG Xiuqin.Effects of GPRC5A on proliferation, oxidative stressand apoptosis of laryngeal cancer cells [J]. Journal ofChinese Physician, 2021, 23(3):359-365.
[14] XIE Linna, ZENG Yanhua, DAI Zichan, et al.Chemical and genetic inhibition of STAT3 sensitizeshepatocellular carcinoma cells to sorafenib induced celldeath[J].International Journal of Biological Sciences,2018,14(5): 577-585.
[15] ZHANG Xuan, ZHANG Silin, SUN Qitong, et al.Compound K induces endoplasmic reticulum stressand apoptosis in human liver cancer cells by regulatingSTAT3[J]. Molecules, 2018, 23(6): 1482.
[16] KIM M S, LEE H S, KIM Y J, et al. MEST inducesTwist-1-mediated EMT through STAT3 activation inbreast cancers[J]. Cell Death and Differentiation, 2019,26(12): 2594-2606.
[17] ZHANG Zhengkui, LI Jisong, GUO Huahu, et al.BRM transcriptionally regulates miR-302a-3p to targetSOCS5/STAT3 signaling axis to potentiate pancreaticcancer metastasis[J]. Cancer Letters, 2019, 449: 215-225.
[18] JOHNSON D E, O’KEEFE R A, GRANDIS J R.Targeting the IL-6/JAK/STAT3 signalling axis incancer[J]. Nature Reviews Clinical Oncology, 2018,15(4): 234-248.
[19] LIN M X, CHEN H,ZHAN X L, et al. MiR-203regulates JAK-STAT pathway in affecting pancreaticcancer cells proliferation and apoptosis by targetingSOCS3[J]. European Review for Medical andPharmacological Sciences, 2019, 23(16): 6906-6913.
[20] 高苏萌, 王卓婷, 徐磊, 等. mTOR/PKM2 和STAT3/c-Myc 信号通路串话调节胃癌能量代谢和酸性微环境的机制研究[J]. 胃肠病学,2020,25(2):76-83.GAO Sumeng,WANG Zhuoting,XU Lei,et al. Mechanismof crosstalk between mTOR / PKM2 and STAT3 /c-Myc signaling pathways in regulating energy metabolismand acidic microenvironment of gastric cancer[J].Chinese Journal of Gastroenterology, 2020,25(2):76-83.

相似文献/References:

[1]王芳胜,熊敦勇,寇辉,等.血清AFP，CEA，CA-199与TAP在肝癌诊断中的应用价值[J].现代检验医学杂志,2015,30(05):148.[doi:10.3969/j.issn.1671-7414.2015.05.047]
　WANG Fang-sheng,XIONG Dun-yong,KOU Hui,et al.Application Value of Serum AFP，CEA，CA-199 and TAP in the Diagnosis of Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2015,30(06):148.[doi:10.3969/j.issn.1671-7414.2015.05.047]
[2]刘冲,唐浩,邓霖,等.血清miRNA-186,miRNA-30c在肝细胞性癌中诊断价值的研究[J].现代检验医学杂志,2016,31(06):44.[doi:10.3969/j.issn.1671-7414.2016.06.012]
　LIU Chong,TANG Hao,DENG Lin,et al.Research of Diagnostic Application of Serum miRNA-186 and miRNA-30c in Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(06):44.[doi:10.3969/j.issn.1671-7414.2016.06.012]
[3]王 蓉,蔡高涛,钟小青,等.血清AFP-L3和GP-73联合检测对原发性肝癌诊断的Meta分析[J].现代检验医学杂志,2019,34(02):72.[doi:10.3969/j.issn.1671-7414.2019.02.019]
　WANG Rong,CAI Gao-tao,ZHONG Xiao-qing,et al.Meta Analysis of Combined Detection of Serum AFP-L3and GP-73 in Diagnosis of Primary Liver Cancer[J].Journal of Modern Laboratory Medicine,2019,34(06):72.[doi:10.3969/j.issn.1671-7414.2019.02.019]
[4]张鑫浩,张涛元,李 俏,等.基于GEO 芯片数据的肝癌关键生物标志物的筛选与鉴定及生物信息学分析[J].现代检验医学杂志,2020,35(04):26.[doi:10.3969/j.issn.1671-7414.2020.04.007]
　ZHANG Xin-hao,ZHANG Tao-yuan,LI Qiao,et al.Screening, Identification and Bioinformatics Analysis of Key Biomarkers for Hepatocellular Carcinoma Based on GEO Chip Data[J].Journal of Modern Laboratory Medicine,2020,35(06):26.[doi:10.3969/j.issn.1671-7414.2020.04.007]
[5]王楷翔a,曹　明a,陈　晖b,等.HCV感染患者血清miR-199和miR-483水平表达及其临床价值[J].现代检验医学杂志,2021,36(05):58.[doi:10.3969/j.issn.1671-7414.2021.05.013]
　WANG Kai-xianga,CAO Minga,CHEN Huib,et al.Expression and Clinical Value of Serum miR-199 and miR-483 inPatients with HCV Infection[J].Journal of Modern Laboratory Medicine,2021,36(06):58.[doi:10.3969/j.issn.1671-7414.2021.05.013]
[6]魏　英,王小林.肝癌组织中lncRNA-PRR34-AS1的表达特性及其对肝癌细胞增殖、迁移的影响和潜在分子机制[J].现代检验医学杂志,2021,36(06):41.[doi:10.3969/j.issn.1671-7414.2021.06.008]
　WEI Ying,WANG Xiao-lin.Expression Characteristics of lncRNA-PRR34-AS1 in Liver Cancer Tissues and Its Effects on Proliferation and Migration of Liver Cancer Cells and Potential Molecular Mechanism[J].Journal of Modern Laboratory Medicine,2021,36(06):41.[doi:10.3969/j.issn.1671-7414.2021.06.008]
[7]吴　琼,郑志存.UBE2T对肝癌细胞增殖、克隆形成及细胞周期的影响及机制研究[J].现代检验医学杂志,2022,37(02):115.[doi:10.3969/j.issn.1671-7414.2022.02.024]
　WU Qiong,CHENG Zhi-cun.Effects of UBE2T on Proliferation, Clone Formation and Cell Cycle of Hepatocellular Carcinoma Cells and Its Molecular Mechanism[J].Journal of Modern Laboratory Medicine,2022,37(06):115.[doi:10.3969/j.issn.1671-7414.2022.02.024]
[8]王俊霞a,贾如江b,霍浩然b,等.肝癌患者血清AHSG，NF-κB表达水平与肝动脉化疗栓塞术预后的相关性研究[J].现代检验医学杂志,2022,37(02):126.[doi:10.3969/j.issn.1671-7414.2022.02.026]
　WANG Jun-xiaa,JIA Ru-jiangb,HUO Hao-ranb,et al.Correlation between Serum AHSG, NF-κB Expression Levels and Prognosis of Hepatic Artery Chemoembolization in Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2022,37(06):126.[doi:10.3969/j.issn.1671-7414.2022.02.026]

更新日期/Last Update: 1900-01-01